Adolescents (age 15 to 21 years) compared with younger children with mature B-cell nonHodgkin's lymphoma (NHL) have been historically considered to have an inferior prognosis. We therefore analyzed the impact of age and other diagnostic factors on the risk of treatment failure in children and adolescents treated on the French-American-British Mature B-Cell Lymphoma 96 (FAB LMB 96) trial.
INTRODUCTION
Mature B-cell non-Hodgkin's lymphoma (NHL), including Burkitt lymphoma (BL), Burkitt leukemia, diffuse large B-cell lymphoma (DLBCL), and primary mediastinal B-cell lymphoma (PMBL) make up approximately 60% of all malignant NHLs that occur in children and adolescents. 1, 2 Multidisciplinary pediatric cooperative group collaborations over the past 25 years have reported a 99% survival rate in limited-risk patients, a 90% survival rate in intermediate-risk patients, and an approximate 70% to 80% overall survival (OS) rate in children with advanced-risk mature B-cell NHL. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Several risk factors have been associated with influencing event-free survival (EFS) in children with mature B-cell NHL. Advanced stage (Murphy classification; ie, stages III and IV v stages I and II) has been associated with a decrease in EFS in children and adolescents with mature B-cell NHL.
12-14, 16 Increased lactate dehydrogenase (LDH) at diagnosis, either Ն 2 ϫ upper limit of normal (ULN) or Ն 1,000 IU has also been associated with a significant decrease in EFS in children and JOURNAL OF CLINICAL ONCOLOGY adolescents with mature B-cell NHL.
6,12-14, 16 CNS involvement has also been an independent poor-risk factor on EFS in children with mature B-cell NHL.
6,12-14, 16 Response to reduction therapy following a reductive phase of chemotherapy in children and adolescents with mature B-cell NHL has also been associated with a significantly inferior EFS, particularly in patients with intermediate and advanced risk. 6, 12, 13 Age, particularly those in the adolescent age group (15 to 21 years), has been suggested to be an additional potential independent prognostic risk factor in EFS in children and adolescents with mature B-cell NHL. Malignant lymphomas are the most common malignancy in the adolescent age group, representing approximately 26% of all malignancies. 17 The first NHL treatment protocol-CCG-551-in the Children's Cancer Group (CCG) from 1977 to 1982 demonstrated that adolescents versus children younger than 15 years of age with BL treated with either cyclophosphamide, vincristine, methotrexate, and prednisone (COMP) or with LSA 2 L 2 therapy (cyclophosphamide, vincristine, methotrexate, daunomycin, prednisone, cytarabine, thioguanine, asparaginase, methotrexate, and carmustine) had a significantly inferior EFS (25% v 70%; P Ͻ .033). [18] [19] [20] Subsequently, the CCG performed a retrospective review of all consecutive CCG studies between 1977 and 1994 that treated children and adolescents with BL or Burkitt-like lymphoma (BLL) and demonstrated a significant decrease in 5-year EFS in adolescents versus younger children treated on similar therapy.
9 Similarly, Patte et al 13 reported that the LMB 89 mature B-cell lymphoma protocol results demonstrated a significantly increased risk of relapse in patients 15 years of age or older. We previously reported the primary results of the French-AmericanBritish Mature B-Cell Lymphoma 96 (FAB LMB 96) study. 6, 10, 12 In this report, we investigated the prognostic risk of adolescent age (15 to 21 years) and other prognostic factors on 5-year EFS and OS in a combined cohort of 1,111 patients with mature B-cell NHL registered and treated on this uniform international cooperative group protocol, which used modern, short, and intensive multiagent chemotherapy.
PATIENTS AND METHODS
FAB LMB 96 was an international study from 161 treatment centers by three cooperative groups: Children's Oncology Group (COG; former CCG institutions in the United States, Canada, and Australia), the United Kingdom Children's Cancer Study Group (UKCCSG), and Societe Francaise d'Oncologie Pediatrique (SFOP; institutions in France and some centers in Belgium and the Netherlands). The protocol was approved by all of the local institutional review boards, and written informed consent was obtained in accordance with the Declaration of Helsinki.ThestudyopenedinMay1996andclosedtopatientaccrualinJune2001.
Eligibility
Children and adolescents with newly diagnosed mature B-lineage NHL with BL, DLBCL, or BLL, according to the Revised European-American Lymphoma (REAL) classification, were eligible. 21 Staging was performed as previously described by Murphy et al. 22 Risk classification was defined as low risk (group A) with resected stage I and abdominal completely resected stage II, high risk (group C) with bone marrow (BM) involvement (L3 blasts Ն 25% and/or CNS disease), and intermediate risk (group B) was all others. 6, 10, 12 Exclusion criteria included congenital or acquired immunodeficiency, prior malignancy, or prior chemotherapy. Therapy for group A involved a nonrandomized confirmatory study of brief chemotherapy 10 ; therapy for groups B and C involved an open randomized trial that investigated the reduction of treatment.
6,12

Treatment
Group A. Patients assigned to group A following resection and diagnostic workup received two courses of cyclophosphamide, vincristine, prednisone, and doxorubicin (COPAD) without intrathecal (IT) chemotherapy, as we have previously described (Fig 1A) . 10 Group B. The details of treatment and random assignment have been described previously.
12 Patients received 7-day, low-dose, prophase cyclophosphamide, vincristine, and prednisone (COP) therapy. Induction therapy consisted of two cycles of fractionated COPAD and high-dose methotrexate 3 g/m 2 (HD-MTX; COPADM). Patients then received two consolidation cycles of cytarabine and HD-MTX (CYM). Treatment concluded with one maintenance phase of COPADM (COPADM-3). Patients received IT chemotherapy prophylaxis during all phases of the therapy. As previously described, patients who did not progress during the first induction course were randomly assigned to therapy reduction with 50% cyclophosphamide delivered in the second induction cycle and/or the elimination of maintenance therapy in a four-arm stratified random assignment. Patients with less than a 20% response on day 7 of COP and patients with residual disease after CYM-1 (that is, the first cycle of CYM) were transferred to rescue group C therapy as outlined below in Figure 1B . 6, 12 Group C. The details of treatment and random assignment are as previously reported. 6 Patients received 7-day low-dose prophase COP. Induction therapy consisted of two cycles of COPADM (with HD-MTX 8 g/m 2 ). Consolidation consisted of high-dose and continuous cytarabine with etoposide (CYVE). Patients with CNS disease did not receive cranial radiation but received additional IT therapy as well as an additional HD-MTX course between consolidation courses ( Figs 1C and 1D , respectively). The first maintenance cycle consisted of COPADM, and three additional maintenance cycles followed in the standard arm of therapy. Patients with favorable disease reassessments were randomly assigned to reduction in chemotherapy during the consolidation phase (CYVE) and the elimination of the three maintenance arms in a two-arm random assignment. 
Definition, Eligibility, and Random Assignment of Adolescents
The upper age limit of enrollment was 21 years at diagnosis in COG institutions and 18 years at diagnosis in SFOP and UKCCSG institutions. The definition of adolescence for subsequent analysis included patients age Ն 15 years at study enrollment. In the randomized analysis, patients were randomly assigned within cooperative groups and strata defined by all combinations of cooperative group, histology (DLBCL or not), stage and LDH level (group B), and CNS positivity (group C). No a priori stratification occurred on the basis of age at enrollment. The distribution of adolescents in the randomized arms was not planned or stratified in advance.
Hematopathology
The morphology and immunophenotype from the initial diagnostic material from each patient was independently evaluated by each of the six hematopathologists from the three national cooperative groups (SFOP: M. Raphael, M.J. Terrier-Lacombe; CCG: M.A. Lones, S.L. Perkins; UKCCSG: K. McCarthy, K.A. Wotherspoon) to establish a diagnosis. The initial standard immunophenotyping panel included antibodies to the following CD antigens: CD20, CD79a, CD3, CD45RO, TDT, CD30, and p80, as described previously. 23, 24 The protocol cases were classified according to the criteria described in the REAL and WHO classifications. 23, 24 At initial evaluation, only clinical information on biopsy site, age, and sex were known. All mediastinal cases were reviewed again by the pathology group at a multiheaded microscope, with full knowledge of all available clinical and cytogenetic information and with careful attention to morphologic features of sclerosis, clear-cell change, and immunophenotype. Because of the limited amount of tissue available, design of the protocol, and the availability of antibodies at the time of review, additional immunohistochemical staining could not be performed, Results of morphologic and immunophenotypic evaluations, as well as diagnosis, were recorded on a standard form for entry into a computer database. A national consensus diagnosis was established for each patient on the basis of independent agreement by the group of hematopathologists or following review by the national group on a multiheaded microscope. A final consensus diagnosis was established for each patient when at least two of the three national consensus diagnoses were in agreement or following review on a multiheaded microscope by all members of the reviewing committee. If morphology was ambiguous between DLBCL and BL leading to discordance by the reviewers, BCL-2 and MIB-1 stains were performed to aid in diagnosis, although this was necessary in less than 10% of cases.
Statistical Methods
The primary end point for analysis was EFS, which was defined as the minimum time to death from any cause, relapse, progressive disease, second malignant neoplasm, or biopsy-positive residual disease at the end of the group C consolidationphase.ThesecondaryendpointwasOS,whichwasthetimetodeath from any cause measured from the start of therapy. Product-limit estimates of EFS and OS probabilities are reported along with Greenwood SEs. The log-rank test and multivariate Cox regression analysis were used to identify significant factors. All reported P values are two-sided. Statistical computations were performed by using STATA version 11 (STATA, College Station, TX).
RESULTS
Demographics
Therewere1,111patientsregisteredonFABLMB96fromMay1996 to June 2001. There were 132, 744, and 235 patients treated on group A, group B, and group C therapy, respectively. Fifteen percent of patients (n ϭ 166) were 15 years old or older. Patients up to age 21 were permitted on study in CCG, but not in the other cooperative groups. Thus, 21% of CCG registered patients were 15 years of age or older compared with 7% for SFOP and 13% for UKCCSG (P Ͻ .001). The frequency of males was 3.3 times higher than that for females in the entire cohort.
Patient demographics and disease characteristics are summarized separately for adolescents (age Ն 15 years) and younger children (age Ͻ 15 years) in Table 1 . There was a difference in the distribution of disease site (P Ͻ .001) with a higher frequency of patients with abdominal/retroperitoneal and head and neck disease among younger children and a higher frequency of patients with primary mediastinal and peripheral node disease among adolescents. The distribution of pathology subtypes was also different (P Ͻ .001); patients with BL/ BLL were more frequent among younger children although patients with DLBCL and mediastinal disease were more frequent among adolescents. There was a difference in distribution of disease stage (P ϭ .003), with a higher percentage of patients younger than age 15 years in stage III. There was also a difference in distribution of BM and CNS positivity (P ϭ .01), with a lower frequency of adolescents being BM-positive compared with younger children (13% v 22%), but frequency was similar for involvement of the CNS in the two age groups (11% v 10%). There was a lower proportion of patients with LDH Ն 2 ϫ institutional upper limit of normal (ULN) among adolescents compared with children younger than age 15 years (34% v 45%; P ϭ .009).
EFS and OS
Median follow-up in patients not experiencing an event was 4.5 years. The estimated 3-year EFS and OS in the entire cohort of patients (N ϭ 1,111) with newly diagnosed mature B-cell NHL treated in the FAB LMB 96 study was 88% Ϯ 1.0% and 90% Ϯ 0.91%, respectively (Fig 2A) . The estimated 3-year EFS in patients who had group A, B, and C therapy was 99% Ϯ 0.75%, 89% Ϯ 1.2%, and 79% Ϯ 2.7%, respectively (P Ͻ .001; Fig 2B) . The estimated 3-year EFS in children younger than age 15 years was similar to that of adolescent patients (89% Ϯ1.0% v84% Ϯ3.4%; Pϭ.15; Fig 3) . There was also no significant difference in the estimated 3-year OS between the two age groups (Ͻ 15 v Ն 15 to 21 years; 91% Ϯ 0.93% v 85% Ϯ 3.2%; P ϭ .083).
Risk Factors for EFS
The log-rank analysis for EFS identified several risk factors that were significant, including prognostic group (P Ͻ .001; Fig 4A) , LDH Ն 2 ϫ ULN (P Ͻ .001), BM/CNS status at diagnosis (P Ͻ .001, Fig 4B) , stage III/IV (P Ͻ .001), and primary site (P Ͻ .001; Fig 4C) .
A Cox multivariate regression analysis was performed that included age (Ն 15 v Ͻ 15 years), prognostic group, stage, primary site, pathology, BM/CNS involvement, and LDH Ն 2 ϫ ULN. The relative failure rate (RFR) estimates, confidence intervals, and P values from this analysis are summarized in Table 2 . Age, prognostic group, stage, and pathology were not significant in this analysis. However, several other variables were significant. LDH Ն 2 ϫ ULN had a relative risk (RR) of 2.0 (P ϭ .003). Primary site was significant (P Ͻ .012) primarily because of higher treatment failure rate associated with mediastinal disease and abdominal/retroperitoneal disease (RFR, 4.5 and 2.7, respectively, v patients with peripheral node primaries). BM-positive/CNS-positive status was significant (P Ͻ .001), primarily because of the higher treatment failure rate associated with combined BM and CNS involvement (RFR, 4.9 v patients with neither BM nor CNS involvement).
DISCUSSION
This trial was the largest multinational cooperative group study in children and adolescents with newly diagnosed mature B-cell NHL. Malignant lymphomas are the most common cancer in adolescents (age 15 to 19 years) and represent almost one in four of all malignant tumors during in this age group.
17,25-27 Furthermore, successful treatment of adolescent cancer has been significantly hampered by several contributing factors, including labile emotional well-being, lack of parental guidance, poor participation in clinical trials, decreased medical insurance coverage, lack of economic resources, and few multidisciplinary programs. [27] [28] [29] Historically, there was general consensus that mature B-cell NHL, especially BL, occurring in adolescence was an independent risk factor for a poorer EFS compared with that occurring in children younger than age 15 years. 9, 13 In the CCG retrospective review of 470 children with BL treated from 1977 to 1994 on front-line CCG B-cell NHL trials, adolescents age Ն 15 years had a significantly inferior survival compared with children younger than age 15 years (35% v 55% to 60%; P Ͻ .002).
9 Similarly, Patte et al 13 demonstrated in patients with intermediate-risk disease given group B therapy in LMB 89 that adolescents had an RR of 6.7 (range, 2.2 to 20.4) for relapse (P Ͻ .006) compared with younger patients (younger than age 15 years) with mature B-cell NHL. Burkhardt et al 26 reviewed the outcome of all adolescents with NHL treated on Berlin-FrankfurtMünster (BFM) 86, BFM 90, and BFM 95 and demonstrated in a multivariate analysis a significantly inferior outcome in adolescents (age 15 to 18 years) with mediastinal large B-cell lymphoma (P Ͻ .054) and a trend in females age Ն 15 years with DLBCL. However, our current, more intensive study demonstrated that age Ն 15 years (adolescents) was not an independent risk factor for inferior EFS, nor was there any indication of a differential effect of age within patient subgroups defined by morphology or sex.
However, the current study did demonstrate that LDH level, mediastinal disease, and BM-positive/CNS-positive disease are independent risk factors for outcome in children and adolescents with mature B-cell NHL treated on modern, short but intensive therapy such as that in FAB LMB 96. A major risk factor identified in this study associated with an inferior outcome was primary site (P Ͻ .012 in multivariate analysis), especially in patients with mediastinal disease (RR of 4.5 relative to patients with peripheral node primaries). Although mediastinal disease represents less than 2% of all NHLs in No. at risk Event-Free Survival (probability)
Event-Free Survival (probability) children younger than age 15 years, its incidence in adolescence increases to approximately 5% to 7%. 26 In an earlier CCG study, Lones et al 23 reported a 75% EFS in children with NHL arising in the mediastinum in which the predominance and histology was PMBL. Similarly, Burkhardt et al 26 reported for the BFM, for NHL studies BFM-86, BFM-90, and BFM-95, an approximately 65% Ϯ 8% EFS in children and adolescents with mediastinal large B-cell lymphoma. Gene expression profiles in adults with PMBL are significantly different from those of other common histologic subtypes of DLBCL.
23,30-32 These findings suggest that short but intensive mature B-cell NHL therapy without radiotherapy, such as that in the FAB LMB 96 study, may not be the optimal therapy for mediastinal disease in children and adolescents. We are currently investigating the role of systemic rituximab with FAB LMB group B therapy in children with advanced mature B-cell NHL, including those with mediastinal disease. 33, 34 Increase in LDH (Ն 2 ϫ ULN) was also associated with a significant decrease in EFS in children and adolescents with mature B-cell NHL treated on the FAB LMB 96 trial (RR, 2.0; P Ͻ .001). Advancedstage disease has previously been demonstrated by several pediatric cooperative groups, including CCG, SFOP, BFM, and the Italian Association of Pediatric Hematology Oncology (AEIOP) to be associated with an inferior outcome 7,9,13,14, 35, 36 In this most recent study, advanced stage was not an independent risk factor for relapse or progression. However, increased LDH at diagnosis as defined differently by different cooperative groups has been historically associated with an inferior outcome in children and adolescents with mature B-cell NHL. ) over 24-versus 4-hour infusion in patients with advanced-stage disease and/or increased LDH levels at diagnosis in children and adolescents with mature B-cell NHL treated on BFM NHL 95 is superior and is associated with a 93% EFS. Similarly, the addition of rituximab to the FAB MB B4 chemotherapy backbone in children and adolescents with mature B-cell NHL with advancedstage disease with or without increased LDH levels is safe and welltolerated.
33, 34 Recently, Meinhardt et al 37 reported good response rates with rituximab in children with intermediate and advanced mature B-cell NHL in a single-dose phase II window design. Randomized and prospective studies will be required to determine whether these and other strategies will significantly increase the EFS in children and adolescents with newly diagnosed advanced-stage mature B-cell NHL and/or with increased LDH levels at diagnosis.
In summary, this large and prospective FAB LMB 96 trial in children and adolescents with newly diagnosed mature B-cell NHL demonstrated that adolescent age (Ն 15 years) is not an independent risk factor for inferior outcome in either univariate or multivariate analysis. Further, increased LDH level (Ն 2 ϫ institutional ULN), mediastinal disease, and combined BM and CNS disease at diagnosis were each independently associated with an increased risk of treatment failure in children and adolescents with mature B-cell NHL who were treated with modern, short but intensive therapy such as that in the FAB LMB 96 study. Other biologic features such as cytogenetics and/or molecular genetics and/or minimal residual disease may also be associated with an increased risk of treatment failure in children and adolescents with mature B-cell NHL.
36,38 Future studies will be required to determine whether different therapeutic strategies can overcome the poor prognostic risk factors discussed herein in children and adolescents with mature B-cell NHL. The results of this analysis will hopefully form the basis of the next risk-adapted childhood and adolescent mature B-cell NHL study.
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